Compare Avalanche Treasury Corporation Class A Common Stock (AVAT) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avalanche Treasury Corporation Class A Common Stock vs AstraZeneca plc — how do they compare? Avalanche Treasury Corporation Class A Common Stock trades at $0.53 (market cap $21.65M), while AstraZeneca plc trades at $169.31 (market cap $253.13B). The key difference: AstraZeneca plc is far larger — about 11691.9× Avalanche Treasury Corporation Class A Common Stock's market cap, and AstraZeneca plc pays a 1.92% dividend while Avalanche Treasury Corporation Class A Common Stock pays none. Which is the better fit depends on your goals.
| AVAT | AZN | |
|---|---|---|
Market Cap | $21.65M | $253.13B |
Sector | Financials | Health |
52-Week High | $10.75 | $209.48 |
52-Week Low | $0.51 | $137.44 |
Enterprise Value | $21.65M | $279.37B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVAT stock trades at $0.506, down 6.3% today, with a bearish technical signal from moving averages. The company shows mixed fundamentals with a low P/E of 12 and P/B of 0.4, but negative cash flow from operations at -$930,710 in 2025. Recent Nasdaq listing news highlights its role as an operating company and digital asset treasury focused on capital allocation across the Avalanche economy.
The outlook remains cautious due to negative operational cash flow and bearish technical indicators. Investment opportunity lies in the discounted valuation multiples, while risks include sustained cash burn and competitive pressures in treasury management services. Market sentiment is neutral with recent media coverage of the Nasdaq debut.
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
